Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 1/20 | 0.33 |
| ▸ | ADRA1A | P35348 | 3/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.31 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.30 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7101523 | 0.88 | ADRA1A (0.31) | ADRA2AADRA1AKDM4EHPGDHSD17B10 | |
| SCHEMBL7098572 | 0.81 | ADRA1A (0.38) | ADRA2AADRA1AKDM4EHPGDHSD17B10 | |
| SCHEMBL7104848 | 0.78 | ADRA2A (0.33) | ADRA2AADRA1A | |
| SCHEMBL7102120 | 0.69 | ADRA2A (0.46) | ADRA2AADRA1A | |
| SCHEMBL7098664 | 0.66 | BRD4 (0.43) | KDM4EHPGDHSD17B10KEAP1NFE2L2 | |
| SCHEMBL7098751 | 0.65 | ADRA2A (0.44) | ADRA2AADRA1A | |
| SCHEMBL1949655 | 0.65 | KDM1A (0.48) | NR3C1KEAP1 | |
| SCHEMBL7100952 | 0.65 | KMO (0.31) | — | |
| SCHEMBL7097707 | 0.63 | ADRA2A (0.45) | ADRA2AADRA1A | |
| SCHEMBL7097621 | 0.63 | ADRA1A (0.45) | ADRA2AADRA1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ABBOTT LABORATORIES | 2003-04-17 | — | — | US | disclosed |
| US-6503935-B1 | Treating urinary incontinence or retrograde ejaculation | ABBOTT LABORATORIES | 2003-01-07 | — | — | US | disclosed |
| EP-1102754-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS ALPHA-1A AGONISTS | ABBOTT LABORATORIES (US) | 2001-05-30 | — | — | EP | disclosed |
| WO-2000007997-A1 | IMIDAZOLES AND RELATED COMPOUNDS AS α1A AGONISTS | ABBOTT LABORATORIES (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030073850-A1 | 4-Imidazole derivatives of benzyl and restricted benzyl sulfonamides, sulfamides, ureas, carbamates, and amides and their use | ADRA1D, ADRB1, ADRA1A | ADRA2A 8/4885ADRA1A 3/4885KDM4E 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.